Why Is the Bacillus Calmette-Guérin BCG Vaccine Not Commonly Used in the United States? The Real Reasons Behind a Deliberate Public-Health Choice

The BCG vaccine is not commonly used in the United States because the country has never had high enough sustained tuberculosis transmission to justify mass infant vaccination, and because the vaccine interferes with tuberculin skin testing, complicates the diagnosis of latent infection, and offers inconsistent protection against adult pulmonary disease. U.S. policy instead relies on targeted screening, contact tracing, and treatment of latent tuberculosis infection.

BCG, or bacillus Calmette-Guérin, is a live attenuated strain of Mycobacterium bovis. It has been given to more than 4 billion people globally since 1921 and remains part of routine infant immunization in most countries with high tuberculosis burden. The American exception is not an oversight or a supply problem. It reflects a risk calculation that has held for decades and continues to shape diagnosis and treatment across the country.

Mechanism: How BCG Trains Immunity and Why That Training Is Imperfect

BCG works by presenting shared mycobacterial antigens to the immune system without causing disease in most recipients. The vaccine is a live, weakened organism that survives briefly inside macrophages, stimulates T-cell responses, and leaves behind memory cells that recognize Mycobacterium tuberculosis antigens. That cross-reactivity is the entire rationale: BCG does not contain M. tuberculosis, but its antigens overlap enough with the pathogen to prime immune recognition.

The depth of that priming is the problem. BCG induces a strong response in infants, whose immune systems are still calibrating, and a weaker, shorter-lived response when given to adults. Protection against disseminated disease in young children, including miliary tuberculosis and tuberculous meningitis, is substantial. Protection against adult pulmonary tuberculosis, the form that drives transmission, is inconsistent across trials. A frequently cited meta-analysis found protective efficacy against pulmonary disease ranging from essentially zero to roughly 80 percent depending on latitude, prior sensitization to environmental mycobacteria, and trial design (Colditz et al., JAMA, 1994). A plain way to put it: BCG reliably protects babies from the worst forms of tuberculosis, but it does not reliably stop adults from coughing the bacteria into the air.

A second, less obvious mechanism matters for the American decision. BCG sensitizes the immune system to tuberculin, the purified protein derivative used in the skin test that has been the backbone of U.S. tuberculosis screening for a century. A vaccinated person will often test positive on a tuberculin skin test without being infected. That false signal forces clinicians to distinguish vaccine response from true infection, which in a low-prevalence country means most positive skin tests in vaccinated people are not tuberculosis at all.

Quantified Context: The Numbers That Drive the Policy

The core quantity in U.S. tuberculosis policy is the case rate. The CDC reported roughly 8,000 to 9,000 tuberculosis cases annually in recent years, a rate near 2.5 per 100,000 population. Global rates in high-burden countries run 100 to 500 per 100,000. The gap is one to two orders of magnitude, and it changes the arithmetic of vaccination entirely.

Consider what mass BCG would have to accomplish to be worth it. In a country with a rate near 2.5 per 100,000, the number of people who would need vaccination to prevent a single case is enormous, because the absolute risk of infection is small. Even a vaccine with 60 percent efficacy against pulmonary disease would prevent a vanishingly small number of cases per million doses when exposure is that rare. In high-burden settings, the same vaccine prevents thousands of cases per million doses because the baseline risk is far higher.

The economics follow the epidemiology. BCG is inexpensive per dose, but a national campaign carries costs beyond the vial: administration, cold chain, documentation, and the downstream diagnostic burden of sorting out vaccine-induced tuberculin positives. That downstream burden is the expensive part. Every vaccinated person who later tests positive on a skin test may need an interferon-gamma release assay, a chest radiograph, and clinical evaluation to rule out infection. In a country ordering millions of tests, that cascade is a large recurring cost with little offsetting benefit at low transmission.

The Skin-Test Interference Problem, in Detail

The tuberculin skin test measures delayed hypersensitivity to purified protein derivative. BCG vaccination produces exactly that hypersensitivity in many recipients, which is why the test cannot distinguish vaccine response from infection. The effect fades over years but can persist for a decade or more, especially if the vaccine was given in infancy and the person was revaccinated. A positive skin test in a BCG-vaccinated person therefore has poor positive predictive value in a low-prevalence country, where most positives are false.

Interferon-gamma release assays, or IGRAs, solve part of this. These blood tests use antigens absent from BCG, so they are not affected by vaccination status. U.S. guidelines increasingly favor IGRAs for screening people with a history of BCG vaccination. But IGRAs are more expensive, require laboratory infrastructure, and are not equally available everywhere. A national BCG campaign would make the cheaper, older skin test even less useful and push more of the screening burden onto the costlier assay. A plain summary: the vaccine contaminates the cheapest screening tool, so you either pay more for blood tests or accept more false positives.

This is the professional caveat that most short explainers miss. The objection to BCG in the United States is not that the vaccine is dangerous or ineffective in children. It is that the vaccine degrades the diagnostic infrastructure that a low-prevalence country depends on to find latent infections and interrupt transmission.

Edge Cases: Where BCG Still Appears in American Medicine

BCG is not absent from U.S. practice. It appears in three narrow contexts.

Infant vaccination for families traveling or relocating to high-burden countries, often arranged through travel clinics or infectious disease specialists rather than routine pediatric care. Occupational protection for some laboratory workers and health care personnel with sustained exposure to drug-resistant tuberculosis, decided case by case. Intravesical BCG, a standard immunotherapy for non-muscle-invasive bladder cancer, given directly into the bladder rather than as a preventive vaccine.

Red-flag warnings worth stating plainly:

Do not give BCG to immunocompromised people, including those with HIV and low CD4 counts, because the live attenuated organism can cause disseminated infection. Do not interpret a positive tuberculin skin test in a BCG-vaccinated person as proof of tuberculosis infection. Do not assume BCG replaces screening, contact tracing, or latent infection treatment. Do not use BCG as a substitute for standard tuberculosis precautions in high-exposure settings.

Misconceptions: What BCG Is Not

The first misconception is that the U.S. abstains because BCG does not work. It does work against the severe pediatric forms of tuberculosis, and that is precisely why high-burden countries use it. The U.S. abstains because the benefit measured against its own case rate does not clear the bar once diagnostic interference is included.

The second misconception is that BCG is withheld because of side effects. Side effects are real but modest: local ulceration, regional lymphadenitis, and rare disseminated infection in immunocompromised recipients. In a high-burden country, those risks are dwarfed by the risk of tuberculosis in unvaccinated infants. In a low-burden country, the risk-benefit calculation flips, but the deciding factor is diagnostic, not toxicologic.

The third misconception is that the policy is universal and permanent. It is neither. It is a recommendation tuned to current epidemiology and revised when that epidemiology changes, which is why targeted vaccination for specific travelers and laboratory personnel is explicitly permitted.

Comparison: BCG Against the American Alternatives

The table makes the trade-off explicit. The U.S. has chosen a strategy built on detection and treatment of latent infection, supported by IGRAs where BCG status would confound the skin test. That strategy is expensive up front but avoids the diagnostic contamination that mass vaccination would introduce.

Timeline: How the American Position Formed

The timeline shows that the American position is a product of falling transmission, not a single decision. As domestic case rates declined, the value of mass vaccination declined with them, while the diagnostic cost of vaccination stayed roughly constant. The policy followed the arithmetic.

Practical Actions: What This Means If You Are Making a Decision

If you are weighing BCG for a child traveling to or living in a high-burden country, arrange the decision with an infectious disease or travel medicine specialist well before departure. Timing matters because the vaccine needs time to produce immunity, and the child's age affects both efficacy and side-effect profile. Do not present this article as a substitute for that consultation.

If you have received BCG and need tuberculosis screening, tell the clinician and request an interferon-gamma release assay rather than relying on a tuberculin skin test. This is the single most practical step that avoids a false-positive cascade.

If you work in a laboratory or health care setting with sustained exposure to drug-resistant tuberculosis, ask occupational health whether targeted BCG is appropriate for your role. The decision is individualized and depends on exposure intensity, available alternatives, and your immune status.

If you have a positive skin test and a history of BCG, do not assume you are infected, and do not assume you are protected. Both assumptions are wrong in different directions, and both can lead to the wrong next step.

Thresholds to keep straight: a case rate near 2.5 per 100,000 signals low transmission and favors the U.S. approach, while rates above roughly 100 per 100,000 favor routine infant BCG. A positive tuberculin skin test in a BCG-vaccinated person requires an IGRA or clinical evaluation before any treatment decision. A CD4 count below 200 in a person with HIV is a reason to avoid BCG, not to give it. Reconcile these thresholds explicitly with a clinician rather than applying them mechanically.

Limitations: What the Evidence Cannot Settle

The evidence base for BCG is old and uneven. Many trials predate modern standards for randomization and follow-up, and the heterogeneity in efficacy estimates has never been fully explained. Latitude, environmental mycobacterial exposure, and BCG strain differences all appear to matter, but the relative contributions are unresolved. The result is that any single efficacy number, including the ranges cited here, carries real uncertainty.

The American policy has not been tested against a modern randomized trial, and it cannot be. You cannot randomize a country to mass vaccination and watch tuberculosis outcomes for decades. The policy rests on observational epidemiology and modeling, which are informative but not definitive. If U.S. transmission rose substantially, the calculation would change, and the recommendation would likely be revisited. That is a statement about the logic of the policy, not a prediction.

Finally, this article describes mechanisms and population-level policy. It does not provide patient-specific diagnosis, treatment plans, or dosing instructions, and it should not be used as a substitute for individualized medical advice.

[Disclaimer] This article is general educational information about vaccine policy and tuberculosis epidemiology, not a diagnosis, treatment plan, or medical recommendation for any individual. It does not promise any outcome and cannot account for your personal risk factors, immune status, or exposure history. Consult a qualified local clinician, such as an infectious disease specialist or travel medicine provider, before making decisions about BCG vaccination or tuberculosis screening. If you have symptoms suggestive of active tuberculosis, such as persistent cough, fever, night sweats, or weight loss, seek medical evaluation promptly or contact local emergency services.